Who Owns Entyvio?

Entyvio's sustainability profile is tied to Takeda's corporate ESG framework. Takeda has committed to achieving carbon neutrality in its operations (Scope 1 and 2) by 2040, with an interim target of a 50 percent reduction by 2035 compared to a 2019 baseline. The company's manufacturing sites in Belgium, Japan, and the U.S. are included in this commitment.

Takeda's Lessines, Belgium facility, a major Entyvio production site, has implemented energy efficiency improvements and waste reduction programs. The company reports on environmental performance, including water consumption, energy use, and waste generation, in its annual integrated report.

On access to medicine, Takeda participates in access initiatives in low- and middle-income countries. However, Entyvio's high cost (approximately $35,000 to $40,000 per year in the U.S.) places it among the more expensive IBD treatments. Patient assistance programs are available in the U.S. through Takeda's Help at Hand program, which provides Entyvio at no cost to eligible patients who lack insurance coverage.

Takeda maintains ethical standards in clinical research. The Entyvio clinical development program, including the GEMINI trials, was conducted with institutional review board oversight and informed consent. Post-marketing surveillance continues through the ENTYVIO Safety Database, which monitors adverse events globally.

Entyvio has not been subject to any product safety recalls. The controversies and challenges surrounding the drug are related to biosimilar competition, pricing, and the complexity of biologic manufacturing.

Biosimilar Competition (2025-2026): The European vedolizumab patent expired in 2025, opening the market to biosimilar competitors. Celltrion and Samsung Bioepis are developing vedolizumab biosimilars. U.S. patent expiry is expected in 2026. Takeda is defending market share through the subcutaneous formulation and long-term safety data, but revenue erosion is expected. This is a standard pharmaceutical lifecycle event, not a safety or ethical controversy.

Pricing and Access: At approximately $35,000 to $40,000 per year in the U.S., Entyvio is among the more expensive IBD treatments. Patient advocacy groups have raised concerns about access and affordability, particularly for underinsured patients. Takeda's Help at Hand patient assistance program partially addresses this by providing free medication to eligible uninsured patients.

Infusion Reactions and Infections: Entyvio carries labeled warnings for infusion-related reactions and increased risk of infections. These are known risks of biologic immunomodulators and are not specific safety controversies. No cases of PML have been reported in Entyvio-treated patients, which is a significant safety advantage over the earlier integrin antagonist Tysabri.

Manufacturing Complexity: Biologic drugs like Entyvio are inherently more complex to manufacture than small-molecule drugs. Supply chain reliability for biologics is an ongoing industry concern. Takeda has not reported significant Entyvio supply disruptions, but the complexity of biologic manufacturing creates inherent supply chain risk.